Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review.

Autor: Patel D; Department of Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA., Chawla J; Department of Foundational Sciences, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA., Blavo C; Department of Public Health and Pediatrics, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA.
Jazyk: angličtina
Zdroj: Cureus [Cureus] 2024 Aug 31; Vol. 16 (8), pp. e68349. Date of Electronic Publication: 2024 Aug 31 (Print Publication: 2024).
DOI: 10.7759/cureus.68349
Abstrakt: The FDA's approval of Pfizer's new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events. It aims to inform healthcare providers about this vital method for safeguarding infant respiratory health through maternal immunization.
Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
(Copyright © 2024, Patel et al.)
Databáze: MEDLINE
Externí odkaz: